公开(公告)号：NZ571280A

公开(公告)日：2011-10-28

申请号：NZ57128007

申请日：2007-03-14

Applicant: VERTEX PHARMA

Inventor： PERNI ROBERT B ,  CHEN MINZHANG ,  JUNG YOUNG CHUN ,  FORSLUND RAYMOND E ,  TANOURY GERALD J ,  BENNANI YOUSSEF ,  ZLOKARNIK GREGOR ,  MALTAIS FRANCOIS

IPC: C07D209/52 ,  A61K31/403 ,  A61K31/422 ,  A61K31/498 ,  A61P31/12 ,  C07C231/20 ,  C07C237/04 ,  C07D403/12 ,  C07D403/14 ,  C07D498/10

Abstract: Disclosed is a keto-enriched alpha-ketoamido compound represented by general formula (I) wherein D is a deuterium atom. Also disclosed is the use of the compounds of formula (I) for treating hepatitis C virus (HCV) infection or a condition mediated by HCV protease

公开(公告)号：PT1934179E

公开(公告)日：2010-07-12

申请号：PT06813568

申请日：2006-08-18

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  MINZHANG CHEN ,  COCHRAN JOHN E

IPC: C07D209/52

公开(公告)号：HK1132988A1

公开(公告)日：2010-03-12

申请号：HK09110787

申请日：2009-11-18

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  CHEN MINZHANG ,  JUNG YOUNG CHUN ,  FORSLUND RAYMOND E

IPC: C07C20060101 ,  C07D20060101

Abstract: This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula (1) wherein the variables R 1 , R 1 ' and R 2 are defined herein and the compound of Formula (1) has an enantiomeric excess (ee) of 55 % or greater.

公开(公告)号：ZA200808645B

公开(公告)日：2009-07-29

申请号：ZA200808645

申请日：2008-10-09

Applicant: VERTEX PHARMA

Inventor： PERNI ROBERT B ,  MINZHANG CHEN ,  CHUN JUNG YOUNG ,  FORSLUND RAYMOND E ,  TANOURY GERALD J ,  YOUSSEF BENNANI ,  GREGOR ZLOKARNIK ,  FRANCOIS MALTAIS

IPC: A61K20090101 ,  A61P20090101 ,  C07C20090101 ,  C07D20090101

公开(公告)号：ZA200801791B

公开(公告)日：2008-12-31

申请号：ZA200801791

申请日：2008-02-25

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  COCHRAN JOHN E ,  MINZHANG CHEN

IPC: A61K20090101 ,  C07D20090101

Abstract: The invention relates to compounds and processes useful for the preparation of protease inhibitors, particularly serine protease inhibitors. The protease inhibitors are useful for treatment of HCV infections.

公开(公告)号：HK1105955A1

公开(公告)日：2008-02-29

申请号：HK07111018

申请日：2007-10-11

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  CHEN MINZHANG ,  JONES ANDREW D ,  NYCE PHILIP L ,  TRUDEAU MARTIN ,  GUERIN DAVID J ,  SNOONIAN JOHN R

IPC: C07B20060101 ,  C07B43/04 ,  C07B57/00 ,  C07D20060101 ,  C07D405/12

Abstract: The invention relates to a process of producing a compound of comprising purifying a mixture of wherein R 8 is a protecting group, and purifying includes chromatographing, selectively crystallizing, or dynamically crystallizing the mixture.

公开(公告)号：AU2007227544A1

公开(公告)日：2007-09-27

申请号：AU2007227544

申请日：2007-03-14

Applicant: VERTEX PHARMA

Inventor： PERNI ROBERT B ,  JUNG YOUNG CHUN ,  TANOURY GERALD J ,  CHEN MINZHANG ,  FORSLUND RAYMOND E ,  BENNANI YOUSSEF ,  MALTAIS FRANCOIS ,  ZLOKARNIK GREGOR

IPC: C07C231/20 ,  A61K31/403 ,  A61K31/422 ,  A61K31/498 ,  A61P31/12 ,  C07C237/04 ,  C07D209/52 ,  C07D403/12 ,  C07D403/14 ,  C07D498/10

Abstract: This invention relates to a process for preparing a compound of Formula 1 wherein: the carbon atoms alpha and beta to the carboxy group are stereocenters; R 1 is independently H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; R' 1 is deuterium such that the deuterium enrichment is at least 50%; R' 2 is -NHR 2 or -OE; R 2 is H, optionally substituted aliphatic, optionally substituted cycloaliphatic, optionally substituted arylaliphatic, optionally substituted heteroaliphatic or optionally substituted heteroarylaliphatic; and E is C 1-6 alkyl or benzyl; wherein the process comprises the steps of: a) forming a salt of a compound of Formula 1, and b) crystallizing said salt to give a compound of greater than 55% enantiomeric excess.

公开(公告)号：PL381358A1

公开(公告)日：2007-05-28

申请号：PL38135805

申请日：2005-03-11

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  CHEN MINZHANG ,  JONES ANDREW D ,  NYCE PHILIP L ,  TRUDEAU MARTIN ,  GUERIN DAVID J ,  SNOONIAN JOHN R

IPC: C07D405/12 ,  C07B43/04 ,  C07B57/00

公开(公告)号：CA2559303A1

公开(公告)日：2005-09-29

申请号：CA2559303

申请日：2005-03-11

Applicant: VERTEX PHARMA

Inventor： TRUDEAU MARTIN ,  GUERIN DAVID J ,  NYCE PHILIP L ,  JONES ANDREW D ,  CHEN MINZHANG ,  TANOURY GERALD J ,  SNOONIAN JOHN R

IPC: C07D405/12 ,  C07B43/04 ,  C07B57/00

Abstract: The invention relates to a process of producing a compound of comprising purifying a mixture of wherein R 8 is a protecting group, and purifying includes chromatographing, selectively crystallizing, or dynamically crystallizing the mixture.

公开(公告)号：CY1121074T1

公开(公告)日：2019-12-11

申请号：CY181100876

申请日：2018-08-22

Applicant: VERTEX PHARMA

Inventor： TANOURY GERALD J ,  NUGENT WILLIAM ALOYSIUS ,  DVORNIKOVS VADIMS ,  ROSE PETER JAMISON

IPC: C07D471/04 ,  C07C51/083

Abstract: ΜέθοδοςπαρασκευήςτηςΈνωσης (1) ήενόςφαρμακευτικώςαποδεκτούάλατοςαυτής: περιλαμβάνει: (α) αντίδρασητηςΈνωσης (Χ): ενόςφαρμακευτικώςαποδεκτούάλατοςαυτήςμετηνΈνωση (Υ): υπότηνπαρουσίαενόςκαταλύτηπαλλαδίουκαιμιαςανθρακικήςή φωσφορικήςβάσηςγιατονσχηματισμότηςΈνωσης (Ζ): ήενόςφαρμακευτικώςαποδεκτούάλατοςαυτής, και (β) αποπροστασίατης Ts ομάδαςτηςΈνωσης (Ζ) γιανασχηματιστείη Ένωση (1) ήέναφαρμακευτικώςαποδεκτόάλαςαυτής.